

oxervate® 
(cenegermin-bkby ophthalmic
solution) 0.002% (20 mcg/mL)

**OXERVATE® is a recombinant human nerve growth factor indicated
for the treatment of neurotrophic keratitis (NK).**



**THE FIRST AND ONLY FDA-APPROVED TREATMENT OPTION
FOR PATIENTS WITH
NEUROTROPHIC KERATITIS^{1,2}**

Important Safety Information

WARNINGS AND PRECAUTIONS


Contact lenses, either therapeutic or corrective, should be removed before applying OXERVATE. Contact lenses may be reinserted 15 minutes after OXERVATE administration.

Please see continuation of Important Safety Information on the following page, complete Important Safety Information on [page 4](#), and read the full Prescribing Information for OXERVATE.

OXERVATE[®] pivotal clinical trials results

The efficacy and safety of OXERVATE[®] for the treatment of neurotrophic keratitis (NK) were studied in a total of 151 patients, evaluated in two 8-week, randomized, multi-center, double-masked, vehicle-controlled studies¹

Patients received study treatment dosed 6 times daily in the affected eye(s) for 8 weeks.¹



*In clinical trials complete corneal healing was defined as absence of staining of the corneal lesion and no persistent staining in the rest of the cornea at 8 weeks of treatment.¹

†Patients without any post-baseline measurements were excluded from the analysis.

In patients who were healed after 8 weeks of treatment with OXERVATE, recurrences occurred in ~20% of patients in Study NGFO212 and 14% of patients in Study NGFO214.¹

Safety in clinical trials

- In clinical trials, the most common adverse reaction was **eye pain following instillation**, which was reported in **approximately 16% of patients**¹
- Eye pain may arise as corneal healing occurs¹
- Other adverse reactions occurring in **1% to 10% of OXERVATE patients** included **corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing, and headache**¹

Important Safety Information (continued)

WARNINGS AND PRECAUTIONS (continued)

Eye Discomfort, such as eye pain, that can be mild to moderate can occur with OXERVATE. Patients should contact their health care provider if a more serious eye reaction occurs.

Please see continuation of Important Safety Information on the following page, complete Important Safety Information on [page 4](#), and read the [full Prescribing Information for OXERVATE](#).

oxervate[®] 
(cenegermin-bkbj ophthalmic solution) 0.002% (20 mcg/mL)

Clinical outcomes

Many patients in the pivotal trials achieved complete corneal healing at week 8*¹



BASELINE³



WEEK 8³

Complete corneal healing*⁵

***Complete corneal healing was defined as absence of staining of the corneal lesion and no persistent staining in the rest of the cornea at 8 weeks of treatment¹**

Images are of a clinical trial patient with Stage 2 NK at baseline and week 8. Evaluations conducted by independent central reading center of the clinical images of corneal fluorescein staining. Not all patients in the trials achieved complete corneal healing. Individual results may vary.⁴

Important Safety Information (continued)

ADVERSE REACTIONS

The most common adverse reaction with OXERVATE (~16%) was eye pain. Other adverse reactions with OXERVATE (1% to 10%) included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing, and headache.

Please see complete Important Safety Information on [page 4](#), and read the [full Prescribing Information for OXERVATE](#).

oxervate[®] 
(cenegermin-bkbj ophthalmic solution) 0.002% (20 mcg/mL)

Recommended dosage and dose administration¹



Instill 1 drop in
the affected eye(s),
6 times daily



At 2-hour
intervals



For
8 weeks

- Patients should remove contact lenses before applying OXERVATE[®] and wait 15 minutes after instillation of the dose before reinsertion¹
- If a dose is missed, treatment should be continued as normal, at the next scheduled administration¹
- If more than 1 topical ophthalmic product is being used, administer the eye drops at least 15 minutes apart to avoid diluting products. Administer OXERVATE 15 minutes prior to using any eye ointment, gel, or other viscous eye drops¹



[Click here to access patient support](#)

Indication

OXERVATE[®] is indicated for the treatment of neurotrophic keratitis (NK).

Important Safety Information

WARNINGS AND PRECAUTIONS

Contact lenses, either therapeutic or corrective, should be removed before applying OXERVATE. Contact lenses may be reinserted 15 minutes after OXERVATE administration.

Eye Discomfort, such as eye pain, that can be mild to moderate can occur with OXERVATE. Patients should contact their health care provider if a more serious eye reaction occurs.

ADVERSE REACTIONS

The most common adverse reaction with OXERVATE (~16%) was eye pain. Other adverse reactions with OXERVATE (1% to 10%) included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing, and headache.

Please read the [full Prescribing Information for OXERVATE](#).

References: **1.** OXERVATE[®] (cenegermin-bkbj) ophthalmic solution 0.002% (20 mcg/mL) [US package insert]. San Mateo, CA: Dompé U.S. Inc.; 2024. **2.** FDA approves first drug for neurotrophic keratitis, a rare eye disease. U.S. Food and Drug Administration; August 22, 2018. Accessed December 3, 2024. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-neurotrophic-keratitis-rare-eye-disease> **3.** Data on File. Clinical Study Report Addendum NGFO214. Feb 2017. Listing 16.2.65-0.1. Patient 07004. **4.** Data on File. Clinical Study Report (NGFO214). Dompé U.S. Inc., 2016. **5.** Bonini S, Lambiase A, Rama P, et al. Phase 2 randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. *Ophthalmology*. 2018;125:1332-1343.